vTv Therapeutics Inc. (VTVT)
| Market Cap | 371.67M +263.0% |
| Revenue (ttm) | 36.84M +216,600.0% |
| Net Income | 2.25M |
| EPS | 0.21 |
| Shares Out | 12.41M |
| PE Ratio | 148.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 58,745 |
| Open | 31.97 |
| Previous Close | 31.02 |
| Day's Range | 29.44 - 32.03 |
| 52-Week Range | 14.00 - 44.00 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 54.33 (+81.4%) |
| Earnings Date | Aug 12, 2026 |
About VTVT
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for VTVT stock is "Strong Buy." The 12-month stock price target is $54.33, which is an increase of 81.40% from the latest price.
News
vTv Therapeutics price target raised to $57 from $49 at BTIG
BTIG analyst Kambiz Yazdi raised the firm’s price target on vTv Therapeutics (VTVT) to $57 from $49 and keeps a Buy rating on the shares. The firm highlights cadisegliatin as…
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-i...
vTv Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $67 price target
vTv Therapeutics Transcript: AGM 2026
The meeting established a quorum and proceeded with votes on director elections, auditor ratification, and executive compensation. All director nominees were elected, Ernst & Young was ratified as auditor, but the advisory vote on executive compensation did not pass.
vTv Therapeutics Proxy statement: Proxy filing
vTv Therapeutics filed a proxy statement on June 10, 2026, providing details for shareholder voting and corporate governance matters.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 3, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
vTv Therapeutics Earnings release
vTv Therapeutics released its earnings on June 1, 2026, summarizing the period's financial results.
vTv Therapeutics reports Q1 EPS $1.65, consensus 21c
Reports Q1 revenue $36.84M, consensus $10M. “We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with ty...
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, ...
vTv Therapeutics to Participate in Upcoming May Investor Conferences
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in...